{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:40:18Z","timestamp":1761093618834,"version":"build-2065373602"},"reference-count":133,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3760,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,10]]},"abstract":"<jats:p>The ketolides represent a new subclass of antibiotics among the macrolide\u2010lincosamide\u2010streptogramin group. Telithromycin, the first ketolide to be awarded approvable status for clinical use, demonstrates in vitro activity against community\u2010acquired respiratory pathogens including penicillin\u2010 and erythromycin\u2010resistant <jats:italic>Streptococcus pneumoniae<\/jats:italic>. An extended half\u2010life permits once\u2010daily oral administration. Telithromycin is a substrate for cytochrome P450 (CYP) 3A4 and also inhibits drugs metabolized by CYP3A4. A relatively high frequency of mild\u2010to\u2010moderate gastrointestinal adverse effects has been reported. Similar clinical and microbiologic efficacy has been demonstrated with oral dosing in comparative clinical trials for community\u2010acquired pneumonia, acute sinusitis, acute exacerbations of chronic bronchitis, and pharyngitis. Although limited data on penicillin\u2010resistant <jats:italic>S. pneumoniae<\/jats:italic> and erythromycin\u2010resistant <jats:italic>Streptococcus pyogenes<\/jats:italic> are available from clinical trials, this drug appears promising for respiratory infections caused by these pathogens.<\/jats:p>","DOI":"10.1592\/phco.21.15.1204.33902","type":"journal-article","created":{"date-parts":[[2004,6,4]],"date-time":"2004-06-04T05:56:42Z","timestamp":1086328602000},"page":"1204-1222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Telithromycin: An Oral Ketolide for Respiratory Infections"],"prefix":"10.1002","volume":"21","author":[{"given":"David T.","family":"Bearden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda M.","family":"Neuhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Garey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1721-1729.2001"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199911)19:6<497::AID-MED3>3.0.CO;2-R"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1112-1113.2000"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1381-1382.2000"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.90"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.3032"},{"key":"e_1_2_1_8_2","first-page":"79","volume-title":"New considerations for macrolides, azalides, streptogramins and ketolides","author":"Bryskier A.","year":"2000"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1999.01203.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1999.01202.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2000.01841.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.577"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.1999.5.183"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.4.578"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.85"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/313452"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1562-1567.2000"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.3.515"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.3.404"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.348"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.8.1354"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.2.167"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.6.905"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.6.649"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.3.297"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.789-793.2001"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.414-417.2000"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00053-X"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1980-1982.2000"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.42.8.2138","article-title":"In vitro activities of the ketolide HMR 3647 against recent gram\u2010positive clinical isolates and Haemophilus influenzae","volume":"42","author":"Barry A.L.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00181-2"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1128\/AAC.42.12.3290","article-title":"In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria","volume":"42","author":"Martinez\u2010Martinez L.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_33_2","first-page":"258","volume-title":"Comparative in vitro activity of two ketolides HMR 3004 and HMR 3647 against Corynebacterium species [abstr and poster]","author":"Riegel P.","year":"1999"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1028"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/AAC.43.4.930","article-title":"In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram\u2010positive bacteria","volume":"43","author":"Malathum K.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1128\/AAC.43.1.166","article-title":"Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis","volume":"43","author":"Hoellman D.B.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.797"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.2.149"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.4.445"},{"key":"e_1_2_1_40_2","first-page":"178","volume-title":"Antipneumococcal activity of telithromycin (HMR 3647) against 584 pneumococci from ten central and eastern European countries [abstr and poster]","author":"Appelbaum P.","year":"2000"},{"key":"e_1_2_1_41_2","first-page":"178","volume-title":"In vitro activity of telithromycin, macrolides and quinolones against respiratory tract pathogens [abstr and poster]","author":"Dubois J.","year":"2000"},{"key":"e_1_2_1_42_2","first-page":"177","volume-title":"Genotype analysis of macrolide resistance and activity of the new ketolide telithromycin (HMR 3647) on group A, C, and G \u03b2\u2010hemolytic streptococci [abstr and poster]","author":"Mazzariol A.","year":"2000"},{"key":"e_1_2_1_43_2","first-page":"176","volume-title":"Activity of telithromycin (HMR 3647) against erythromycin\u2010susceptible and \u2010resistant isolates of Streptococcus pneumoniae and Streptococcus pyogenes from Austria [abstr and poster]","author":"Mittermayer H.","year":"2000"},{"key":"e_1_2_1_44_2","first-page":"177","volume-title":"The comparative in vitro activity of telithromycin (HMR 3647) against isolates of Streptococcus pyogenes (Lancefield Serogroup A) circulating in Great Britain, Northern Ireland, and the Republic of Ireland during late 1999 [abstr and poster]","author":"Morrissey I.","year":"2000"},{"key":"e_1_2_1_45_2","first-page":"178","volume-title":"Activity of telithromycin (HMR 3647) against susceptible and well\u2010characterized erythromycin A\u2010resistant isolates of Streptococcus pyogenes [abstr and poster]","author":"Negri M.","year":"2000"},{"key":"e_1_2_1_46_2","first-page":"177","volume-title":"Antibiotic resistance of S. pyogenes and S. pneumoniae strains isolated from infections of outpatients in Germany, 1999\u20132000 [abstr and poster]","author":"Reinert R.","year":"2000"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.332"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/AAC.43.12.3039","article-title":"In vitro activities of ketolide HMR3647, macrolides, and other antibiotics against Lactobacillus, Leuconostoc, and Pediococcus isolates","volume":"43","author":"Zarazaga M.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.6.703"},{"key":"e_1_2_1_50_2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/JCM.38.4.1444-1448.2000","article-title":"Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies","volume":"38","author":"Davies T.A.","year":"2000","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1509"},{"key":"e_1_2_1_52_2","first-page":"179","volume-title":"Distribution of erythromycin A resistance determinants in Spanish Streptococcus pneumoniae isolates and comparative activity of telithromycin (HRM 3647) [abstr and poster]","author":"Morosini M.","year":"2000"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.624-626.2001"},{"key":"e_1_2_1_54_2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/AAC.42.4.965","article-title":"In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine)","volume":"42","author":"Hoppe J.E.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00022-4"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.353-355.2001"},{"key":"e_1_2_1_57_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1128\/AAC.43.4.983","article-title":"In vitro activities of ketolides HMR 3647 and HMR 3004, levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis","volume":"43","author":"Saez\u2010Nieto J.A.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_58_2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.42.5.1127","article-title":"Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans","volume":"42","author":"Goldstein E.J.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_59_2","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Schulin T.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2801"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.2019"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.1.115"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.4.467"},{"key":"e_1_2_1_64_2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/AAC.42.6.1515","article-title":"In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae","volume":"42","author":"Roblin P.M.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.23-29.2001"},{"volume-title":"Data on file","year":"2001","author":"Aventis Pharmaceuticals.","key":"e_1_2_1_66_2"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2999-3002.2000"},{"key":"e_1_2_1_68_2","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1128\/AAC.42.12.3279","article-title":"In vitro activity of the new ketolide HMR3647 in comparison with those of macrolides and pristinamycins against Enterococcus spp","volume":"42","author":"Torres C.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.1.181-182.2000"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2848-2852.2000"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.5.665"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.1.51"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1749-1753.2000"},{"key":"e_1_2_1_74_2","first-page":"257","volume-title":"Post\u2010antibiotic effect (PAE) and bactericidal activity of HMR 3647 and other antimicrobial agents against respiratory pathogens [abstr and poster]","author":"Dubois J.","year":"1999"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.741"},{"key":"e_1_2_1_76_2","unstructured":"LenfantB. SultanE. WableC. et al.Pharmacokinetics of 800\u2010mg once\u2010daily dosing of the ketolide telithromycin (HMR 3647) in healthy young volunteers. Presented at the 5th international conference on macrolides azalides streptogramins ketolides and oxazolidinones Seville Spain January 2628 2000."},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.170-175.2001"},{"key":"e_1_2_1_78_2","unstructured":"SultanE. LenfantB. WableC. et al.Pharmacokinetics profile of telithromycin (HMR 3647) 800 mg once\u2010daily in elderly volunteers. Presented at the 5th international conference on macrolides azalides streptogramins ketolides and oxazolidinones Seville Spain January 2628 2000."},{"key":"e_1_2_1_79_2","unstructured":"LenfantB. PerretC. PascualM..The bioavailability of telithromycin (HMR 3647) a new once\u2010daily ketolide antimicrobial is unaffected by food. Presented at the 5th international conference on macrolides azalides streptogramins ketolides and oxazolidinones Seville Spain January 2628 2000."},{"key":"e_1_2_1_80_2","unstructured":"SerieysC. CantalloubeC. SolerP. et al.Telithromycin (HMR 3647) achieves high and sustained concentrations in bronchopulmonary tissues. Presented at the 5th international conference on macrolides azalides streptogramins ketolides and oxazolidinones Seville Spain January 2628 2000."},{"key":"e_1_2_1_81_2","first-page":"20","volume-title":"Penetration of telithromycin (HMR 3647) into bronchial mucosa (BM), epithelial lining fluid (ELF), and alveolar macrophages (AM) following multiple oral doses [abstr and poster]","author":"Andrews J.","year":"2000"},{"key":"e_1_2_1_82_2","unstructured":"GiaH. RoederV. NamourR. et al.Telithromycin (HMR 3647) achieves high and sustained concentrations in white blood cells in man. Presented at the 5th international conference on macrolides azalides streptogramins ketolides and oxazolidinones Seville Spain January 2628 2000."},{"key":"e_1_2_1_83_2","first-page":"15","volume-title":"Penetration of the ketolide, HMR 3647, in cantharidin\u2010induced blister fluid [abstr and poster]","author":"Sultan E.","year":"1998"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2457"},{"key":"e_1_2_1_85_2","first-page":"480A","article-title":"Penetration of macrolides into pulmonary sites of infection","volume":"16","author":"Bearden D.","year":"1999","journal-title":"Infect Med"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.3.249"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70202-6"},{"key":"e_1_2_1_88_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/44.1.1","article-title":"Pneumococcal macrolide resistance: myth or reality?","volume":"44","author":"Amsden G.W.","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_1_89_2","first-page":"189","volume-title":"In vivo pharmacodynamic activity of HMR 3647, a new ketolide [abstr and poster]","author":"Vesga O.","year":"1997"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(20)30278-6"},{"key":"e_1_2_1_91_2","unstructured":"SultanE. NamourF. MauriacC. et al.Telithromycin (HMR 3647) a new ketolide antimicrobial is metabolized and excreted mainly in faeces in man. Presented at the 5th international conference on macrolides azalides streptogramins ketolides and oxazolidinones Seville Spain January 2628 2000."},{"key":"e_1_2_1_92_2","first-page":"3","volume-title":"HRM 3647, a new ketolide antimicrobial, does not affect the reliability of low\u2010dose, triphasic oral contraceptives [abstr and poster]","author":"Scholtz H.","year":"1999"},{"key":"e_1_2_1_93_2","unstructured":"ScholtzH. PretoriusS. WesselsD. et al.Telithromycin (HMR 3647) a new ketolide antimicrobial does not affect the pharmacodynamics or pharmacokinetics of warfarin. Presented at the 5th international conference on macrolides azalides streptogramins ketolides and oxazolidinones Seville Spain January 2628 2000."},{"volume-title":"Ketek (telithromycin). Briefing document for the Food and Drug Administration Anti\u2010Infective Drug Products Advisory Committee meeting. Data on file","year":"2001","author":"Aventis Pharmaceuticals.","key":"e_1_2_1_94_2"},{"key":"e_1_2_1_95_2","first-page":"32","volume-title":"Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae [abstr and poster]","author":"Craig W.","year":"2000"},{"key":"e_1_2_1_96_2","first-page":"28","volume-title":"Pharmacokinetic (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community\u2010acquired pneumonia (CAP) [abstr and poster]","author":"Drusano G.","year":"2000"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.6.1826"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.suppl_2.37"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.4.615-650.2000"},{"key":"e_1_2_1_100_2","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/AAC.42.8.1944","article-title":"Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils","volume":"42","author":"Vazifeh D.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.511-521.2000"},{"key":"e_1_2_1_102_2","first-page":"490","volume-title":"Efficacy and tolerability of telithromycin (HMR 3647) vs. high\u2010dose amoxicillin in the treatment of community\u2010acquired pneumonia [abstr and poster]","author":"Hagberg L.","year":"2000"},{"key":"e_1_2_1_103_2","first-page":"471","volume-title":"Oral telithromycin (HMR3647; 800 mg od) is well tolerated and as effective as oral clarithromycin (500 mg bid) in community\u2010acquired pneumonia (CAP) in adults [abstr and poster]","author":"Tellier G.","year":"2000"},{"key":"e_1_2_1_104_2","first-page":"472","volume-title":"Oral telithromycin (HMR 3647; 800 mg OD) for 7\u201310 days is well tolerated and as effective as oral trovafloxacin (200 mg OD) for 7\u201310 days in community\u2010acquired pneumonia (CAP) in adults [abstr and poster]","author":"Pullman J.","year":"2000"},{"key":"e_1_2_1_105_2","first-page":"489","volume-title":"Efficacy and tolerability of a 5\u2010day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with COPD [abstr and poster]","author":"Aubier M.","year":"2000"},{"key":"e_1_2_1_106_2","first-page":"471","volume-title":"Oral telithromycin (HMR3647; 800 mg od) for 5 days is well tolerated and as effective as cefuroxime axetil (500 mg bid) for 10 days in adults with acute exacerbations of chronic bronchitis (AECB) [abstr and poster]","author":"DeAbate C.","year":"2000"},{"key":"e_1_2_1_107_2","first-page":"471","volume-title":"Oral telithromycin (HMR 3647; 800 mg OD) for 5 days and 10 days is well tolerated and as effective as amoxicillin\/clavulanic acid (500\/125 mg TID) for 10 days in acute maxillary sinusitis (AMS) in adults [abstr and poster]","author":"Tellier G.","year":"2000"},{"key":"e_1_2_1_108_2","first-page":"489","volume-title":"Efficacy of 5 days telithromycin (HMR 3647) vs. 10 days penicillin V in the treatment of pharyngitis in adults [abstr and poster]","author":"Norrby S.","year":"2000"},{"key":"e_1_2_1_109_2","first-page":"472","volume-title":"Oral telithromycin (HMR 3647; 800 mg OD) for 5 days is well tolerated and as effective as clarithromycin (250 mg BID) for 10 days in group A \u03b2\u2010hemolytic streptococcal pharyngitis\/tonsillitis [abstr and poster]","author":"Ziter P.","year":"2000"},{"key":"e_1_2_1_110_2","first-page":"490","volume-title":"Telithromycin (HMR 3647), a new once\u2010daily ketolide antimicrobial, provides effective treatment of community\u2010acquired pneumonia [abstr and poster]","author":"Carbon C.","year":"2000"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360402"},{"key":"e_1_2_1_112_2","first-page":"470","volume-title":"Efficacy of the ketolide telithromycin (HMR3647) in the treatment of bacteremia associated with community\u2010acquired pneumonia [abstr and poster]","author":"Leroy B.","year":"2000"},{"key":"e_1_2_1_113_2","first-page":"471","volume-title":"Efficacy of telithromycin (HMR 3647), a new ketolide antimicrobial, in community\u2010acquired pneumonia caused by atypical pathogens [abstr and poster]","author":"Leroy B.","year":"2000"},{"key":"e_1_2_1_114_2","first-page":"490","volume-title":"Efficacy and tolerability of a 5\u2010day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis [abstr and poster]","author":"Roos K.","year":"2000"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)90003-1"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200009000-00037"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_2.S218"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1086\/513768"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00255-7"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3395-3401.2000"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1053\/srin.2000.18066"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1086\/315853"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00155-2"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70257-9"},{"volume-title":"E.E.S. (erythromycin ethylsuccinate) package insert","year":"1997","author":"Abbott Laboratories.","key":"e_1_2_1_125_2"},{"volume-title":"Biaxin (clarithromycin) package insert","year":"2001","author":"Abbott Laboratories.","key":"e_1_2_1_126_2"},{"volume-title":"Zithromax (azithromycin) package insert","year":"2001","author":"Pfizer","key":"e_1_2_1_127_2"},{"key":"e_1_2_1_128_2","unstructured":"SultanE. CantelloubeC. PatatA. et al.Telithromycin (HMR 3647) the first ketolide antimicrobial does not require dosage adjustments in patients with hepatic impairment. Presented at the 10th European congress of clinical microbiology and infectious diseases Stockholm Sweden May 2831 2000."},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1999.01203.x"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(00)00167-3"},{"issue":"4","key":"e_1_2_1_131_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/1120009X.2000.11782307","article-title":"Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?","volume":"12","author":"Harding I.","year":"2000","journal-title":"J Chemother"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.10.1399"},{"key":"e_1_2_1_133_2","unstructured":"GotfriedM. NeuhauserM. GareyK. et al.In vitroStreptococcus pneumoniaeresistance: correlations with outcomes in patients with respiratory infections. Presented at the 21st international congress of chemotherapy Birmingham England July 47 1999."},{"volume-title":"Aventis receives approvable letter from U.S. Food and Drug Administration for Ketek\u2122 (telithromycin) tablets","year":"2001","author":"Aventis Pharmaceuticals.","key":"e_1_2_1_134_2"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.15.1204.33902","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.15.1204.33902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:03:26Z","timestamp":1761048206000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.15.1204.33902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":133,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["10.1592\/phco.21.15.1204.33902"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.15.1204.33902","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2001,10]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}